27 results about "Phage lysis" patented technology

The utility model discloses a bacteriophage separating device for culturing bacteriophages, which relates to the technical field of bacteriophage culturing and separating devices and comprises a base, vertical columns fixedly mounted at four corners of the bottom of the base, a container arranged at the upper end of the base, a feeding pipe communicated and fixedly mounted at the upper end of the container, and a discharging pipe communicated and fixedly mounted at the bottom end of the container. A sealing plug is arranged at the discharge pipe, and one end of the sealing plug is in threaded connection with the interior of the discharge pipe and can block the sealing plug. According to the bacteriophage separation device for culturing the bacteriophage, the annular plate is driven to rotate by rotating the connecting piece, the annular plate is divided into a plurality of strip shapes by the strip-shaped grooves, and the annular plate can block the filter groove, so that the annular container is separated from the container, and a bacteriophage lysis solution is prevented from flowing back into the container from the filter groove. The backflow phenomenon is avoided, so that the phage can keep high purity in the separation process, and a high-quality phage sample is provided for subsequent experiments and applications.

The invention relates to the technical field of biological medicine, in particular to a composition for blocking formation of phage treatment tolerance and application of the composition. The composition comprises a folium ilicis purpurea ethyl acetate extraction active component and a clostridium perfringens specific bacteriophage, the folium ilicis purpurea ethyl acetate extraction active component is prepared from the following components in percentage by mass: 8 to 15 percent of protocatechuic acid and 5 to 10 percent of ethyl gallate, and the mass ratio of the protocatechuic acid to the ethyl gallate is (1.5 to 1) to (2.5 to 1); the clostridium perfringens specific bacteriophage is a virulent bacteriophage capable of specifically cracking a clostridium perfringens NetB toxin positive strain. According to the invention, the shallow thought that the existing compounding technology only pursues synergistic sterilization is subverted, and a deep synergistic mode of bacteriophage splitting attack and folium ilicis purpurea component disintegration bacterial defense program is proposed and verified for the first time. And the formation of tolerance is fundamentally blocked, so that a more thorough and more lasting treatment effect is realized, and the comprehensive production performance of animals is accidentally and greatly improved on the basis of the treatment effect.

The invention discloses application of bacteriophage lyase LysFEC14 in preparation of a composition for resisting gram-negative bacteria. The amino acid sequence of the bacteriophage lyase LysFEC14 is as shown in SEQ ID NO.01. The invention further discloses a preparation method of the bacteriophage lyase LysFEC14. The antibacterial composition disclosed by the invention shows high-efficiency cracking activity on various escherichia coli standard strains, still has a remarkable antibacterial effect at low concentration, and provides a green and efficient novel antibacterial composition for preventing and treating gram-negative bacterium infection, particularly drug-resistant escherichia coli infection.

The invention discloses recombinant bacteriophage lyase and application thereof. The amino acid sequence of the recombinant bacteriophage lyase E8-3 is as shown in SEQ ID NO: 43, and an in-vitro minimum inhibitory concentration experiment shows that the recombinant bacteriophage lyase E8-3 has a bacteriostatic effect on helicobacter pylori and acinetobacter baumannii, and particularly has a wide application prospect in the development of anti-helicobacter pylori drugs.

The invention relates to the technical field of biology, in particular to a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. The invention provides a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. A broad-spectrum bacteriophage lyase mutant nucleic acid release liquid containing protein with an amino acid sequence as shown in SEQ ID NO: 1 is adopted; the compound can efficiently act on two important clinical drug-resistant bacteria, namely methicillin-resistant staphylococcus aureus MRSA and vancomycin-resistant enterococcus VRE, at the same time. Through unique molecular design and preparation process optimization, the lyase shows excellent synchronous wall breaking capacity, cell wall destruction can be completed in an extremely short time, and the nucleic acid release efficiency is remarkably superior to that of a traditional method.

This invention discloses a strain of Salmonella choleraesuis phage SCP512 and its applications, belonging to the field of microbial technology. Salmonella choleraesuis phage SCP512 is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 47021, dated February 4, 2026. It belongs to the family Myocaudae within the class Caudata. This phage SCP512 possesses multivalent lytic characteristics, excellent biological properties and environmental adaptability, and can disrupt pathogen biofilm formation. It addresses the technical problems of existing phages, such as limited lytic spectrum, insufficient coverage of common foodborne pathogens, weak biofilm removal ability, and limited application potential in practical food matrices.

A bacteriophage lytic enzyme and its application. The name of the bacteriophage lytic enzyme is PlyNJ3; the gene fragment encoding the lytic enzyme PlyNJ3 is amplified from streptococcus suis by PCR, and a prokaryotic expression vector plasmid pET32a-PlyNJ3 containing the PlyNJ3 gene is constructed, the recombinant plasmid is obtained by transforming DH5 alpha competent cells, and the protein is massively expressed in an escherichia coli expression system. Then, the lytic enzyme PlyNJ3 is purified by affinity purification medium, the high-efficiency expression of the lytic enzyme PlyNJ3 in vitro is realized, and the lytic effect of the lytic enzyme PlyNJ3 on different serotypes of streptococcus suis, streptococcus agalactiae and other common streptococci is verified in vitro. The bacteriophage lytic enzyme PlyNJ3 prepared by the application can selectively lyse target pathogenic bacteria, and has a good application prospect in the development of new bacteriophage drugs.

The application provides a microcapsule of prophage lysozyme and a preparation method thereof, and the preparation method comprises the following steps: transforming an expression plasmid containing a recombinant Sply181 lysozyme gene into engineering bacteria, collecting bacterial bodies after culture induction, obtaining lysozyme through ultrasonic crushing, centrifugation and metal ion affinity chromatography purification; preparing the enzyme into a prophage lysozyme mother liquor by mixing with a calcium chloride solution, adding an emulsifier and an anti-acid antioxidant, homogenizing and emulsifying to form a core material suspension; mixing the core material suspension with a sodium alginate-agarose colloidal solution, homogenizing, dropping into a calcium lactate solution through a spraying or extrusion method, solidifying, collecting microcapsule primary bodies and performing low-temperature vacuum drying and shaping; and mixing the dried microcapsule primary bodies with talc, fishy peptide, vanillin and taurine, and then performing a powder coating operation to obtain the microcapsule of prophage lysozyme. The application has the effects of removing endotoxins in engineering bacteria and adding broad-spectrum attractants, and can significantly improve the feeding desire and intake of fish.

The invention provides a prophage lyase microcapsule and a preparation method thereof, and the preparation method comprises the following steps: transforming expression plasmids containing recombinant Sply181 lyase genes into engineering bacteria, collecting thalli after culture induction, and obtaining lyase through ultrasonic disruption, centrifugation and metal ion affinity chromatography purification; preparing the prophage lyase and a calcium chloride solution into prophage lyase mother liquor, adding an emulsifier and an anti-acid and anti-oxidant, and homogenizing and emulsifying to form core material suspension; mixing and homogenizing the core material suspension and the sodium alginate-agarose colloidal solution, dropwise adding the mixture into a calcium lactate solution through a spraying or extrusion method for curing, collecting a microcapsule primary body, and performing low-temperature vacuum drying and shaping; and mixing the dried microcapsule primary body with talcum powder, fishy peptide, vanillin and taurine, and then carrying out powder coating operation to prepare the prophage lyase microcapsule. The feed additive has the effects of removing toxins in engineering bacteria and adding a broad-spectrum phagostimulant, and can remarkably improve the appetite and intake of fishes.

The present application relates to a kind of bacteriophage lytic enzyme LysSPYS2, containing bacteriophage lytic enzyme composition and its application, bacteriophage lytic enzyme LysSPYS2 sequence is as shown in SEQ ID No.1, the bacteriophage lytic enzyme has high-efficiency, broad-spectrum bactericidal effect;It has lytic effect to a variety of bacteria, can be used as bacteriostatic agent;Further, the bacteriophage lytic enzyme is combined with polymyxin B, can exert synergistic antibacterial effect, significantly reduce the amount of antibiotic;The bacteriophage lytic enzyme can also be used with Magnolol, realize outstanding bacteriostatic effect.

This invention relates to a phage lysin LysSPYS1, a composition containing the phage lysin, and their applications. The sequence of the phage lysin LysSPYS1 is shown in SEQ ID No. 1. This phage lysin exhibits highly efficient and broad-spectrum bactericidal activity; it has a lytic effect on a variety of bacteria and can be used as a bacteriostatic agent. Furthermore, combining this phage lysin with polymyxin B can exert a synergistic antibacterial effect, significantly reducing the amount of antibiotics used. The phage lysin can also be used in combination with magnolol to achieve a prominent antibacterial effect.

The invention discloses a preparation method for inducing staphylococcus aureus extracellular vesicles by utilizing phage lyase PlySs2 and application of the staphylococcus aureus extracellular vesicles. The extracellular vesicles are obtained by subjecting staphylococcus aureus in a logarithmic phase or a stable phase to PlySs2 treatment, filtration, ultrafiltration and ultracentrifugation purification. Compared with natural extracellular vesicles, the extracellular vesicles induced by the PlySs2 are higher in yield and good in uniformity, the toxicity is remarkably reduced, and the extracellular vesicles can be used for immunogenicity research and research and development of vaccine compositions.

The invention discloses a protein for enhancing foreign protein expression and application thereof. The target protein-OMP43 recombinant protein can be obtained by fusing and connecting the protein OMP43 to the C end of the target protein, so that the expression level of the target protein in a heterologous expression system is improved. The recombinant protein En6-OMP43 is constructed and obtained by taking bacteriophage lyase En6 as an example. Experimental results show that after the OMP43 is fused, the antibacterial activity of the recombinant protein lyase on acinetobacter baumannii is maintained. The protein OMP43 serving as an expression enhancing element is high in universality, simple and convenient to construct and suitable for being modularly applied to foreign protein expression and preparation.

The invention relates to the technical field of biology, in particular to listeria monocytogenes bacteriophage lyase Lys039 and application, and the amino acid sequence of the lyase Lys039 is shown as SEQ ID NO.1; the lyase Lys039 has the cracking activity, and shows the cracking activity on all listeria; the molecular marker has a wide splitting spectrum, but cannot split staphylococcus, bacillus subtilis and gram-negative bacteria, and has specificity. The sterilization capability is relatively high, and the concentration dependence is realized; good temperature tolerance is achieved, and the highest temperature can reach 80 DEG C; the listeria monocytogenes strain has the advantages that the listeria monocytogenes strain shows bactericidal activity in the pH range of 3-12, the listeria monocytogenes viable count can be obviously reduced in both acidic and alkaline environments, and when the pH is 6, the listeria monocytogenes strain has higher activity and shows higher acid and alkali resistance.

This invention discloses a strain of Salmonella choleraesuis phage SCP531 and its applications, belonging to the field of microbial technology. Salmonella choleraesuis phage SCP531 is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 47020, dated February 4, 2026. It belongs to the family Myocaudae within the class Caudata. This phage SCP531 exhibits broad-spectrum and highly efficient lytic activity, excellent biological characteristics and stability, and can disrupt pathogen biofilm formation, thus solving the technical problems of narrow phage lytic spectrum, insufficient biofilm removal ability, and limited application potential in food matrices in existing technologies.

The invention discloses a bacteriophage lyase Lys162 and an application of the bacteriophage lyase Lys162 in preparation of an antibacterial product. The bacteriophage lyase has a remarkable splitting effect on gram-negative bacteria and gram-positive bacteria, so that the bacteriophage lyase can be used as a broad-spectrum antibacterial protein. For example, the antibacterial effect on pseudomonas aeruginosa, klebsiella pneumoniae and streptococcus is remarkable. The antibacterial protein has relatively high temperature tolerance and pH tolerance, can replace antibiotics, and is applied to prevention and treatment of bacterial diseases as an external medicine or an internal medicine and sterilization of medical instruments and medical places; and the product can also be used as an additive to be applied to the fields of feed processing, food industry, animal husbandry, beer industry, aquaculture, cosmetic production, fruit preservation and the like.

This invention relates to the field of biomedical technology, disclosing a broad-spectrum phage composition for the prevention and control of porcine atrophic rhinitis and its applications, particularly involving Pasteurella multocida phage SD-PM1 and Bordetella bronchiseptica phage SD-Bb1, with accession numbers CCTCC NO: M20232599 and CCTCC NO: M20232589, respectively. The phages and their compositions of this invention exhibit strong broad-spectrum lytic activity against both Pasteurella multocida and Bordetella bronchiseptica. These phages can be used alone or in combination with other phages to prepare drugs for the prevention and treatment of porcine respiratory diseases caused by single or mixed infections of Pasteurella multocida and Bordetella bronchiseptica, with particularly significant effects against porcine atrophic rhinitis. Furthermore, the phages of this invention are all virulent phages with a broad lytic spectrum, good acid and heat resistance, and can be applied in various practical scenarios.

The invention relates to the technical field of environmental protection and health, in particular to a multidrug-resistant vibrio bacteriophage and application thereof. The multi-drug-resistant vibrio phage is a vibrio phage YTLJ-VBY1 which is preserved in Guangdong Microbial Culture Collection Center (GDMCC), the address of the GDMCC is No.59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, the preservation date is January 22, 2024, the multi-drug-resistant vibrio phage is classified and named as the vibrio phage, and the preservation number is GDMCC NO: 64301-B1. The vibrio bacteriophage can effectively remove multi-drug-resistant vibrios, and antibiotic resistance of residual vibrio variants can be lost or greatly weakened after the vibrio bacteriophage is cracked and killed by the vibrio bacteriophage.

The invention discloses a microbial bactericide and application thereof. The microbial bactericide comprises the following components: a functional microbial complex microbial inoculant, a targeting bacteriophage composition, a pH-responsive nanogel carrier and an auxiliary agent, wherein the functional microorganism complex microbial inoculant comprises a bacterial strain which is separated from deep-sea sediments and screened by a plate confrontation method, and the diameter of an inhibition zone of the bacterial strain on at least one target pathogenic bacterium is greater than or equal to 15mm; the targeted bacteriophage composition comprises at least two lytic bacteriophages, and the lytic bacteriophages are used for respectively and specifically splitting different types of pathogenic bacteria including ralstonia solanacearum, pseudomonas syringae and Erwinia; four mechanisms of competitive occupation, antibacterial substance inhibition, bacteriophage lysis and induction system resistance are integrated, and the limitation of a single action mode is broken through.

The invention discloses a recombinant vector for expressing bacteriophage lyase and a construction method and application of the recombinant vector. The recombinant vector for expressing the bacteriophage lyase is based on a pichia pastoris expression system. The recombinant vector for expressing the bacteriophage lyase comprises a bacteriophage lyase gene, a multiple cloning site, a replication start site, a promoter, a terminator, an alpha-factor signal peptide and a resistance selection marker. According to the recombinant vector of the bacteriophage lyase provided by the invention, the lyase gene is recombined onto the vector, so that the expressed lyase can be used for developing a novel feed additive for preventing necrotic enteritis of poultry directly or after being prepared into a preparation, and a food preservative for controlling clostridium perfringens pollution in meat; or as a therapeutic drug for local or systemic infections.

The application provides a recombinant bacillus subtilis producing phage lytic enzyme LysJPP58 and a construction method and application thereof. The recombinant bacillus subtilis integrates the lytic enzyme LysJPP58 into the genome of a host bacterium bacillus subtilis, wherein the lytic enzyme LysJPP58 is derived from a staphylococcus aureus phage, and an amino acid sequence of the lytic enzyme LysJPP58 is shown as SEQ ID NO. 1. The recombinant bacillus subtilis can effectively secrete the LysJPP58 protein with lytic activity, and can significantly lyse staphylococcus aureus. The recombinant bacillus subtilis has the characteristics of safety, sustainability and industrial fermentation production, and provides a new technical approach for the development of animal health, food safety and medical antibacterial preparations.

A carbomer hydrogel for maintaining the natural skin microflora and suppressing pathogenic bacteria that contains lytic enzymes and / or highly stable crude / purified Staphylococcus aureus phage lysates with a titer of at least 107 pfu / g of gel and crude / purified Cutibacterium acnes phage lysates with a titer of at least 105 pfu / g of gel.

This invention belongs to the field of phage application technology and discloses a phage lysis protein and its applications. The lysis protein E provided by this invention, as shown in SEQ ID NO.7, is a novel protein, unlike any previously reported phage lysis protein E sequence. The TS protein of this invention exhibits strong lysis ability at position 21, regardless of whether it contains leucine or proline. This discovery breaks with the conventional understanding that proline at position 21 of phage lysis protein E is an essential residue for phage lysis function, providing a new and important theoretical basis for the study of phage lysis of bacteria. It also provides a new theoretical basis and strategic direction for the development of new functional lysis proteins E, and is expected to be applied to the development of new, more powerful phage lysis proteins E for the preparation of drugs or formulations that inhibit pathogenic bacteria.

The present invention relates to the field of anti-infection treatment and prevention. The present invention relates to a bacteriophage lysin chimera or a variant thereof and a use thereof. The bacteriophage lysin chimera or the variant thereof of the present invention comprises a catalytic domain, a binding domain and a linker. The lysin and the chimera thereof of the present invention have improved biophysical properties, have excellent applicability, and are suitable for cosmetics, medical devices, disinfectants and / or therapeutic applications.

The invention belongs to the technical field of microbial prevention and treatment, and particularly relates to a bacteriophage for splitting pan-drug-resistant klebsiella pneumoniae in a wide spectrum, a bacteriophage composition and application of the bacteriophage composition. Specifically, the invention provides a bacteriophage PhiKpn-02 for splitting pan-drug-resistant klebsiella pneumoniae in a wide spectrum, the bacteriophage is relatively wide in splitting spectrum, relatively efficient splitting activity can be maintained in a wide temperature range and under acid-base conditions, and the application potential of the bacteriophage PhiKpn-02 in different environments is ensured. The bacteriophage is sequentially combined with other bacteriophages to achieve a synergistic antibacterial effect, the antibacterial time can be prolonged, and an effective method and treatment thought are provided for prevention and treatment of pan-drug-resistant klebsiella pneumoniae infectious diseases, so that the bacteriophage has good practical application value.

This invention discloses a novel bacteriophage for targeting Klebsiella pneumoniae and its preparation method, relating to the fields of microbiology and medical technology; comprising the following steps: S1: providing an environmental sample containing a lytic bacteriophage; S2: processing and filtering the environmental sample to obtain an initial filtrate containing the bacteriophage; S3: co-culturing the initial filtrate with the host bacterium Klebsiella pneumoniae CRKP-2503074069 to obtain a culture mixture; S4: filtering the culture mixture to obtain a bacteriophage lysate. The bacteriophage of this invention contains a glycoside hydrolase family 28 domain, a capsular polysaccharide depolymerase; this enables it not only to lyse bacteria but also to enzymatically lyse the thick capsule of Klebsiella pneumoniae, explaining the formation of its characteristic target-like plaques and endowing it with the additional ability to disrupt biofilm structures.

The present application relates to a kind of methods for surface immobilization of bacteriophage lytic enzyme that infects gram-negative bacteria, the present application utilizes bacteriophage lytic enzyme LysSSE1 that can infect G-bacteria, by molecular cloning technology, amino acid type connector and / or affinity ligand SiAP1 / SiAP2 screened from database are introduced from the perspective of molecular biology, construct recombinant lytic enzyme containing peptide chain, then incubated with NaCl and Tween 20, 100 rpm oscillation 30-60 min.The method of the present application successfully realizes the stable and efficient sterilization of lytic enzyme in external environment, the immobilized enzyme containing amino acid chain obtained not only maintains the activity of original lytic enzyme, but also improves its resistance to environmental change and repeated sterilization ability, solves the problem of difficult addition of chemical type connector and environmental unfriendliness etc.It has important practical significance for effectively controlling the surface attachment pollution of G-bacteria in environment.